Skip to content

DMT: all studies

Page 20 of 160: studies 191 to 200 of 1,593, newest first. Back to the DMT overview

Research

The flattening of spacetime hierarchy of the N,N-dimethyltryptamine brain state is characterized by harmonic decomposition of spacetime (HADES) framework.

National Science Review May 1, 2024 Jakub Vohryzek, Joana Cabral, Christopher Timmermann et al. 13 citations

The human brain is a complex system, whose activity exhibits flexible and continuous reorganization across space and time. The decomposition of whole-brain recordings into harmonic modes has revealed a repertoire of gradient-like activity patterns associated with distinct brain functions. However, the way these activity patterns are expressed over time with their changes in various brain states...

DOI: 10.1093/nsr/nwae124 (opens in new tab) Full text (opens in new tab) DMT Harmonic modes Spatio-temporal brain dynamics Psychedelics hallucinogens +9

The Potential Use of Dimethyltryptamine against Ischemia-reperfusion Injury of the Brain

Journal of Neuroscience and Neurological Disorders April 19, 2024 Attila Kovács, Anna Mathe, Ede Frecska 2 citations

Ischemia-Reperfusion Injury (IRI) is the outcome of two intertwined pathological processes resulting from the shortage of blood flow to tissues and the subsequent restoration of circulation to a previously ischemic area. IRI (sometimes just one side of the dyad) remains one of the most challenging problems in several branches of emergency medicine. Mitochondrial and endoplasmic reticulum...

The potential of 5‐methoxy‐N,N‐dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action

Addiction Biology April 1, 2024 Stephan Tap 12 citations

Abstract Alcohol use disorder (AUD) remains one of the most prevalent psychiatric disorders worldwide with high economic costs. Current treatment options show modest efficacy and relapse rates are high. Furthermore, there are increases in the treatment gap and few new medications have been approved in the past 20 years. Recently, psychedelic‐assisted therapy with psilocybin and lysergic acid...

Experiências anômalas com ayahuasca e DMT: uma leitura psicossocial

March 22, 2024 Ricardo Assarice Dos Santos

dos quais 100% alegaram vivenciar ao menos algum tipo de experincia anmala.Os resultados revelaram uma diversidade de experincias, destacando a prevalncia de Experincias Msticas (95%), Experincias Visionrias (93,5%) e Experincias Fora do Corpo (86,8%).A pesquisa tambm identificou considervel prevalncia de experincias ufolgicas (42,9%), correlacionadas com fatores psicossociais como crenas

Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties

Molecular Psychiatry March 14, 2024 Pol Puigseslloses, Gabriel Ketsela, Nicola Weiss et al. 23 citations

Abstract Recent studies have sparked renewed interest in the therapeutic potential of psychedelics for treating depression and other mental health conditions. Simultaneously, the novel psychoactive substances (NPS) phenomenon, with a huge number of NPS emerging constantly, has changed remarkably the illicit drug market, being their scientific evaluation an urgent need. Thus, this study aims to...

Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial.

European Neuropsychopharmacology March 1, 2024 Marcelo Falchi-Carvalho, Isabel Wießner, Sérgio Ruschi B Silva et al. 25 citations

Psychedelics are being increasingly examined for their therapeutic potential in mood disorders. While the acute effects of ayahuasca, psilocybin, and lysergic acid diethylamide (LSD) last over several hours, inhaled N,N-Dimethyltryptamine (DMT) effects last around 10 min, which might provide a cost- and time-effective alternative to the clinical application of oral psychedelics. We aimed at...

DOI: 10.1016/j.euroneuro.2023.12.006 (opens in new tab) Full text (opens in new tab) Entheogens Clinical trial Dose-response study Mood disorders +6

The Clinical Potential of Dimethyltryptamine: Breakthroughs into the Other Side of Mental Illness, Neurodegeneration, and Consciousness

Psychoactives February 26, 2024 Frankie A. Colosimo, Philip Borsellino, Reese I. Krider et al. 8 citations

The human brain is an extraordinarily complex organ responsible for all aspects of cognition and control. Billions of neurons form connections with thousands of other neurons, resulting in trillions of synapses that create a vast and intricate network. This network is subjected to continuous remodeling that adapts to environmental and developmental changes. The resulting neuroplasticity is...

Defining 5-MeO-DMT in Historical and Cultural Contexts

World Futures February 17, 2024 Azul Delgrasso 4 citations

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a psychedelic and entheogenic compound that has been used for centuries by Indigenous Peoples in the Amazon, Caribbean, and more recently in communities in Northern Mexico in ceremonial practices and to connect with nature. In recent years, there has been growing interest in 5-MeO-DMT to treat mental health conditions such as depression, anxiety...

DOI: 10.1080/02604027.2024.2330255 (opens in new tab) Radical photochemical reactions Alkaloids

Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.

ACS Medicinal Chemistry Letters February 8, 2024 Navoda Jayakodiarachchi, Mallory A Maurer, Daniel C Schultz et al. 6 citations

Herein, we report the synthesis and characterization of a novel set of substituted indazole-ethanamines and indazole-tetrahydropyridines as potent serotonin receptor subtype 2 (5-HT2) agonists. Specifically, we examine the 5-HT2 pharmacology of the direct indazole analogs of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and related serotonergic tryptamines, and highlight the need for rigorous...

DOI: 10.1021/acsmedchemlett.3c00566 (opens in new tab) Full text (opens in new tab) Drug development Serotonin receptors Medicinal chemistry Pharmacology

Effects of DMT on mental health outcomes in healthy volunteers

Scientific Reports February 7, 2024 Christopher Timmermann, Richard J. Zeifman, David Erritzøe et al. 37 citations

Abstract Psilocybin, a serotonergic psychedelic, is being increasingly researched in clinical studies for the treatment of psychiatric disorders. The relatively lengthy duration of oral psilocybin’s acute effects (4–6 h) may have pragmatic and cost-effectiveness limitations. Here, we explored the effects of intravenous (IV) N,N-Dimethyltryptamine (DMT), a closely related, but faster-acting...

DOI: 10.1038/s41598-024-53363-y (opens in new tab) Full text (opens in new tab) Psychedelics Mental health treatment DMT Research Clinical trials +1